Christina Elliott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christina Elliott has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- George S. Baillie
School of Cardiovascular and Metabolic Health University of Glasgow UK
10 shared publications - Christopher Linington
University of Glasgow
6 shared publications - Richard Killick
Centre for Healthy Brain Aging, IoPPN, King’s College London, London SE5 9RT, UK
5 shared publications Ariel Arthur
Institute of Infection, Immunity and Inflammation, University of Glasgow, UK
3 shared publications- Edgar Meinl
Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München
3 shared publications - Elena M. Ribe
Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London SE5 8AF, UK
3 shared publications
Latest Publications
- 1 December 2026
- Published by American Physiological Society in Advances in Physiology Education
- Vol. 50 (4) , 1294-1298
Amino Acid—Who R You? An interactive browser-based game for learning amino acid properties
Amino Acid—Who R You? uses three complementary game modes to practice amino acid deduction, classification, and retrieval. Learner-adjustable cues vary support across names, codes, structures, and side-chain properties. Its account-free browser format enables flexible taught or independent consolidation of chemistry that underpins later reasoning about protein function in physiology.
- 1 December 2026
- Published by American Physiological Society in Advances in Physiology Education
- Vol. 50 (4) , 1294-1298
Amino Acid—Who R You? An interactive browser-based game for learning amino acid properties
Amino Acid—Who R You? uses three complementary game modes to practice amino acid deduction, classification, and retrieval. Learner-adjustable cues vary support across names, codes, structures, and side-chain properties. Its account-free browser format enables flexible taught or independent consolidation of chemistry that underpins later reasoning about protein function in physiology.
- Open Access
Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression
Lithium is prescribed as a mood stabilizer for bipolar disorder and severe depression. However, the mechanism of action of lithium is unknown and there are major side effects associated with prolonged medication. This motivates a search for safer alternative drug repurposing candidates. Given that the drug mechanism may be encoded in transcriptional changes, we generated the gene expression profile for acute lithium treatment of cortical neuronal cultures. We found that the lithium-associated transcription response harbors a significant component that is the reverse of that seen in human brain samples from patients with major depression, bipolar disorder, and a mouse model of depression. Interrogating publicly available drug-driven expression data, we found that cardiotonic steroids drive gene expression in a correlated manner to our acute lithium profile. An analysis of the psychiatric medication cohort of the Norwegian Prescription Database showed that cardiotonic prescription is associated with a lower incidence of lithium prescription. Our transcriptional and epidemiological observations point towards cardiotonic steroids as possible repurposing candidates for lithium. These observations motivate a controlled trial to establish a causal connection and genuine therapeutic benefit in the context of depression.
Open AccessTranscription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression
Lithium is prescribed as a mood stabilizer for bipolar disorder and severe depression. However, the mechanism of action of lithium is unknown and there are major side effects associated with prolonged medication. This motivates a search for safer alternative drug repurposing candidates. Given that the drug mechanism may be encoded in transcriptional changes, we generated the gene expression profile for acute lithium treatment of cortical neuronal cultures. We found that the lithium-associated transcription response harbors a significant component that is the reverse of that seen in human brain samples from patients with major depression, bipolar disorder, and a mouse model of depression. Interrogating publicly available drug-driven expression data, we found that cardiotonic steroids drive gene expression in a correlated manner to our acute lithium profile. An analysis of the psychiatric medication cohort of the Norwegian Prescription Database showed that cardiotonic prescription is associated with a lower incidence of lithium prescription. Our transcriptional and epidemiological observations point towards cardiotonic steroids as possible repurposing candidates for lithium. These observations motivate a controlled trial to establish a causal connection and genuine therapeutic benefit in the context of depression.
- 27 December 2024
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 42 (2-3) , 61-64
Do thyroid hormones determine the neurotoxicity of cadmium?
Α recent experimental study on rats has shown that the neurotoxicity of cadmium (Cd) could be associated with the levels of thyroid hormones. We, herein, discuss these findings and focus on the effects of the exposure to Cd on a widely-employed neurotoxicity marker: the activity of brain acetylcholinesterase (AChE). Moreover, we assess the novelty of the association between Cd-induced neurotoxicity and the levels of thyroid hormones, reflect on the poor understanding of the nature and the mechanisms defining the interplay between Cd and thyroid function, and highlight the complexity of achieving reliable and comparable experimental assessments of Cd-induced neurotoxicity through the employment of AChE activity as a marker. Finally, we express the opinion that the systematic co-assessment of the levels of thyroid hormones as well as their pharmacological manipulation could prove to be very useful in the elucidation of the mechanisms underlying Cd-induced neurotoxicity.
- 27 December 2024
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 42 (2-3) , 61-64
Do thyroid hormones determine the neurotoxicity of cadmium?
Α recent experimental study on rats has shown that the neurotoxicity of cadmium (Cd) could be associated with the levels of thyroid hormones. We, herein, discuss these findings and focus on the effects of the exposure to Cd on a widely-employed neurotoxicity marker: the activity of brain acetylcholinesterase (AChE). Moreover, we assess the novelty of the association between Cd-induced neurotoxicity and the levels of thyroid hormones, reflect on the poor understanding of the nature and the mechanisms defining the interplay between Cd and thyroid function, and highlight the complexity of achieving reliable and comparable experimental assessments of Cd-induced neurotoxicity through the employment of AChE activity as a marker. Finally, we express the opinion that the systematic co-assessment of the levels of thyroid hormones as well as their pharmacological manipulation could prove to be very useful in the elucidation of the mechanisms underlying Cd-induced neurotoxicity.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 11-13
Technology-enhanced learning in Pharmacology through non-linear storytelling
There is a growing body of literature highlighting the potential of game-based learning (GBL) in creating immersive, highly engaging, active learning experiences. Furthermore, advances in digital technology along with the demand for online learning during the COVID-19 pandemic has brought digital GBL to the forefront of innovative teaching practice. Here, I share some of the digital GBL strategies we have developed to support our pharmacology teaching. In collab¬oration with our students, we have co-created a series of “choose your own adventure” style games using Twine; an open-source storytelling game engine. Importantly, we have shown that adoption of these GBL approaches is highly effective in promoting student engagement, subject understanding, and learning community. Furthermore, I also dis¬cuss how AI tools can allow educators with little knowledge or experience of game development to create unique and engaging learning experiences for their students.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 11-13
Technology-enhanced learning in Pharmacology through non-linear storytelling
There is a growing body of literature highlighting the potential of game-based learning (GBL) in creating immersive, highly engaging, active learning experiences. Furthermore, advances in digital technology along with the demand for online learning during the COVID-19 pandemic has brought digital GBL to the forefront of innovative teaching practice. Here, I share some of the digital GBL strategies we have developed to support our pharmacology teaching. In collab¬oration with our students, we have co-created a series of “choose your own adventure” style games using Twine; an open-source storytelling game engine. Importantly, we have shown that adoption of these GBL approaches is highly effective in promoting student engagement, subject understanding, and learning community. Furthermore, I also dis¬cuss how AI tools can allow educators with little knowledge or experience of game development to create unique and engaging learning experiences for their students.
- Open Access
- 29 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
How we stepped up to support others
From diagnosis and disclosure to leading change, two neurodivergent researchers recount their experiences setting up peer support networks at their universities.
- 29 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessHow we stepped up to support others
From diagnosis and disclosure to leading change, two neurodivergent researchers recount their experiences setting up peer support networks at their universities.
- Open Access
- 7 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11219
Neurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer’s Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil
The pan Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor fasudil acts as a vasodilator and has been used as a medication for post-cerebral stroke for the past 29 years in Japan and China. More recently, based on the involvement of ROCK inhibition in synaptic function, neuronal survival, and processes associated with neuroinflammation, it has been suggested that the drug may be repurposed for neurodegenerative diseases. Indeed, fasudil has demonstrated preclinical efficacy in many neurodegenerative disease models. To facilitate an understanding of the wider biological processes at play due to ROCK inhibition in the context of neurodegeneration, we performed a global gene expression analysis on the brains of Alzheimer’s disease model mice treated with fasudil via peripheral IP injection. We then performed a comparative analysis of the fasudil-driven transcriptional profile with profiles generated from a meta-analysis of multiple neurodegenerative diseases. Our results show that fasudil tends to drive gene expression in a reverse sense to that seen in brains with post-mortem neurodegenerative disease. The results are most striking in terms of pathway enrichment analysis, where pathways perturbed in Alzheimer’s and Parkinson’s diseases are overwhelmingly driven in the opposite direction by fasudil treatment. Thus, our results bolster the repurposing potential of fasudil by demonstrating an anti-neurodegenerative phenotype in a disease context and highlight the potential of in vivo transcriptional profiling of drug activity.
- 7 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11219
Open AccessNeurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer’s Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil
The pan Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor fasudil acts as a vasodilator and has been used as a medication for post-cerebral stroke for the past 29 years in Japan and China. More recently, based on the involvement of ROCK inhibition in synaptic function, neuronal survival, and processes associated with neuroinflammation, it has been suggested that the drug may be repurposed for neurodegenerative diseases. Indeed, fasudil has demonstrated preclinical efficacy in many neurodegenerative disease models. To facilitate an understanding of the wider biological processes at play due to ROCK inhibition in the context of neurodegeneration, we performed a global gene expression analysis on the brains of Alzheimer’s disease model mice treated with fasudil via peripheral IP injection. We then performed a comparative analysis of the fasudil-driven transcriptional profile with profiles generated from a meta-analysis of multiple neurodegenerative diseases. Our results show that fasudil tends to drive gene expression in a reverse sense to that seen in brains with post-mortem neurodegenerative disease. The results are most striking in terms of pathway enrichment analysis, where pathways perturbed in Alzheimer’s and Parkinson’s diseases are overwhelmingly driven in the opposite direction by fasudil treatment. Thus, our results bolster the repurposing potential of fasudil by demonstrating an anti-neurodegenerative phenotype in a disease context and highlight the potential of in vivo transcriptional profiling of drug activity.
- Open Access
- 14 February 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (1)
Bridging integrator 1 protein loss in Alzheimer’s disease promotes synaptic tau accumulation and disrupts tau release
Polymorphisms associated with BIN1 (bridging integrator 1) confer the second greatest risk for developing late-onset Alzheimer’s disease. The biological consequences of this genetic variation are not fully understood; however, BIN1 is a binding partner for tau. Tau is normally a highly soluble cytoplasmic protein, but in Alzheimer’s disease, tau is abnormally phosphorylated and accumulates at synapses to exert synaptotoxicity. The purpose of this study was to determine whether alterations in BIN1 and tau in Alzheimer’s disease promote the damaging redistribution of tau to synapses, as a mechanism by which BIN1 polymorphisms may increase the risk of developing Alzheimer’s disease. We show that BIN1 is lost from the cytoplasmic fraction of Alzheimer’s disease cortex, and this is accompanied by the progressive mislocalization of phosphorylated tau to synapses. We confirmed proline 216 in tau as critical for tau interaction with the BIN1-SH3 domain and showed that the phosphorylation of tau disrupts this binding, suggesting that tau phosphorylation in Alzheimer’s disease disrupts tau–BIN1 associations. Moreover, we show that BIN1 knockdown in rat primary neurons to mimic BIN1 loss in Alzheimer’s disease brain causes the damaging accumulation of phosphorylated tau at synapses and alterations in dendritic spine morphology. We also observed reduced release of tau from neurons upon BIN1 silencing, suggesting that BIN1 loss disrupts the function of extracellular tau. Together, these data indicate that polymorphisms associated with BIN1 that reduce BIN1 protein levels in the brain likely act synergistically with increased tau phosphorylation to increase the risk of Alzheimer’s disease by disrupting cytoplasmic tau–BIN1 interactions, promoting the damaging mis-sorting of phosphorylated tau to synapses to alter synapse structure and reducing the release of physiological forms of tau to disrupt tau function.
- 14 February 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (1)
Open AccessBridging integrator 1 protein loss in Alzheimer’s disease promotes synaptic tau accumulation and disrupts tau release
Polymorphisms associated with BIN1 (bridging integrator 1) confer the second greatest risk for developing late-onset Alzheimer’s disease. The biological consequences of this genetic variation are not fully understood; however, BIN1 is a binding partner for tau. Tau is normally a highly soluble cytoplasmic protein, but in Alzheimer’s disease, tau is abnormally phosphorylated and accumulates at synapses to exert synaptotoxicity. The purpose of this study was to determine whether alterations in BIN1 and tau in Alzheimer’s disease promote the damaging redistribution of tau to synapses, as a mechanism by which BIN1 polymorphisms may increase the risk of developing Alzheimer’s disease. We show that BIN1 is lost from the cytoplasmic fraction of Alzheimer’s disease cortex, and this is accompanied by the progressive mislocalization of phosphorylated tau to synapses. We confirmed proline 216 in tau as critical for tau interaction with the BIN1-SH3 domain and showed that the phosphorylation of tau disrupts this binding, suggesting that tau phosphorylation in Alzheimer’s disease disrupts tau–BIN1 associations. Moreover, we show that BIN1 knockdown in rat primary neurons to mimic BIN1 loss in Alzheimer’s disease brain causes the damaging accumulation of phosphorylated tau at synapses and alterations in dendritic spine morphology. We also observed reduced release of tau from neurons upon BIN1 silencing, suggesting that BIN1 loss disrupts the function of extracellular tau. Together, these data indicate that polymorphisms associated with BIN1 that reduce BIN1 protein levels in the brain likely act synergistically with increased tau phosphorylation to increase the risk of Alzheimer’s disease by disrupting cytoplasmic tau–BIN1 interactions, promoting the damaging mis-sorting of phosphorylated tau to synapses to alter synapse structure and reducing the release of physiological forms of tau to disrupt tau function.
- Open Access
- 20 September 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-13
A role for APP in Wnt signalling links synapse loss with β-amyloid production
In Alzheimer’s disease (AD), the canonical Wnt inhibitor Dickkopf-1 (Dkk1) is induced by β-amyloid (Aβ) and shifts the balance from canonical towards non-canonical Wnt signalling. Canonical (Wnt-β-catenin) signalling promotes synapse stability, while non-canonical (Wnt-PCP) signalling favours synapse retraction; thus Aβ-driven synapse loss is mediated by Dkk1. Here we show that the Amyloid Precursor Protein (APP) co-activates both arms of Wnt signalling through physical interactions with Wnt co-receptors LRP6 and Vangl2, to bi-directionally modulate synapse stability. Furthermore, activation of non-canonical Wnt signalling enhances Aβ production, while activation of canonical signalling suppresses Aβ production. Together, these findings identify a pathogenic-positive feedback loop in which Aβ induces Dkk1 expression, thereby activating non-canonical Wnt signalling to promote synapse loss and drive further Aβ production. The Swedish familial AD variant of APP (APPSwe) more readily co-activates non-canonical, at the expense of canonical Wnt activity, indicating that its pathogenicity likely involves direct effects on synapses, in addition to increased Aβ production. Finally, we report that pharmacological inhibition of the Aβ-Dkk1-Aβ positive feedback loop with the drug fasudil can restore the balance between Wnt pathways, prevent dendritic spine withdrawal in vitro, and reduce Aβ load in vivo in mice with advanced amyloid pathology. These results clarify a relationship between Aβ accumulation and synapse loss and provide direction for the development of potential disease-modifying treatments.
- 20 September 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-13
Open AccessA role for APP in Wnt signalling links synapse loss with β-amyloid production
In Alzheimer’s disease (AD), the canonical Wnt inhibitor Dickkopf-1 (Dkk1) is induced by β-amyloid (Aβ) and shifts the balance from canonical towards non-canonical Wnt signalling. Canonical (Wnt-β-catenin) signalling promotes synapse stability, while non-canonical (Wnt-PCP) signalling favours synapse retraction; thus Aβ-driven synapse loss is mediated by Dkk1. Here we show that the Amyloid Precursor Protein (APP) co-activates both arms of Wnt signalling through physical interactions with Wnt co-receptors LRP6 and Vangl2, to bi-directionally modulate synapse stability. Furthermore, activation of non-canonical Wnt signalling enhances Aβ production, while activation of canonical signalling suppresses Aβ production. Together, these findings identify a pathogenic-positive feedback loop in which Aβ induces Dkk1 expression, thereby activating non-canonical Wnt signalling to promote synapse loss and drive further Aβ production. The Swedish familial AD variant of APP (APPSwe) more readily co-activates non-canonical, at the expense of canonical Wnt activity, indicating that its pathogenicity likely involves direct effects on synapses, in addition to increased Aβ production. Finally, we report that pharmacological inhibition of the Aβ-Dkk1-Aβ positive feedback loop with the drug fasudil can restore the balance between Wnt pathways, prevent dendritic spine withdrawal in vitro, and reduce Aβ load in vivo in mice with advanced amyloid pathology. These results clarify a relationship between Aβ accumulation and synapse loss and provide direction for the development of potential disease-modifying treatments.
- Open Access
- 1 April 2018
- Published by AME Publishing Company in Annals of Research Hospitals
- Vol. 2 (4) , 4
Brain N-acetylaspartate accumulation in Canavan disease is not neurotoxic per se: the implications of the first gene replacement therapy study to demonstrate successful post-symptomatic treatment in mice
- 1 April 2018
- Published by AME Publishing Company in Annals of Research Hospitals
- Vol. 2 (4) , 4
Open AccessBrain N-acetylaspartate accumulation in Canavan disease is not neurotoxic per se: the implications of the first gene replacement therapy study to demonstrate successful post-symptomatic treatment in mice
- Open Access
- 19 October 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (3) , 306-317
Amyloid β synaptotoxicity is Wnt‐PCP dependent and blocked by fasudil
Introduction: Synapse loss is the structural correlate of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to synapses. We previously demonstrated that Aβ induces Dickkopf‐1 (Dkk1), which in turn activates the Wnt–planar cell polarity (Wnt‐PCP) pathway to drive tau pathology and neuronal death.Methods: We compared the effects of Aβ and of Dkk1 on synapse morphology and memory impairment while inhibiting or silencing key elements of the Wnt‐PCP pathway.Results: We demonstrate that Aβ synaptotoxicity is also Dkk1 and Wnt‐PCP dependent, mediated by the arm of Wnt‐PCP regulating actin cytoskeletal dynamics via Daam1, RhoA and ROCK, and can be blocked by the drug fasudil.Discussion: Our data add to the importance of aberrant Wnt signaling in Alzheimer's disease neuropathology and indicate that fasudil could be repurposed as a treatment for the disease.
- 19 October 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (3) , 306-317
Open AccessAmyloid β synaptotoxicity is Wnt‐PCP dependent and blocked by fasudil
Introduction: Synapse loss is the structural correlate of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to synapses. We previously demonstrated that Aβ induces Dickkopf‐1 (Dkk1), which in turn activates the Wnt–planar cell polarity (Wnt‐PCP) pathway to drive tau pathology and neuronal death.Methods: We compared the effects of Aβ and of Dkk1 on synapse morphology and memory impairment while inhibiting or silencing key elements of the Wnt‐PCP pathway.Results: We demonstrate that Aβ synaptotoxicity is also Dkk1 and Wnt‐PCP dependent, mediated by the arm of Wnt‐PCP regulating actin cytoskeletal dynamics via Daam1, RhoA and ROCK, and can be blocked by the drug fasudil.Discussion: Our data add to the importance of aberrant Wnt signaling in Alzheimer's disease neuropathology and indicate that fasudil could be repurposed as a treatment for the disease.